In vivo antagonism with zidovudine plus stavudine combination therapy

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 321-325

  Havlir, Diane V ^a,j   Tierney, Camlin ^c   Friedland, Gerald H ^d   Pollard, Richard B ^e   Smeaton, Laura ^c   Sommadossi, Jean Pierre ^f   Lawrence, Fox ^g   Kessler, Harold ^h   Fife, Kenneth H ⁱ   Richman, Douglas D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^j NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; STAVUDINE; ZIDOVUDINE;

EID: 0033914469     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315683     Document Type: Article

References (14)

1. 1. Pollard RB. D4T nucleoside combinations for HIV. Antiviral Res 1996; 29: 101-4.
2. 2. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998; 12:F71-7.
3. 3. Ho H-T, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33:844-9.
4. 4. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39:1376-8.
5. 5. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-6.
6. 6. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two-and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996; 173:355-64.
7. 7. Sørensen AM, Nielsen C, Mathiesen LR, Nielsen JO, Hansen JE. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993; 25:365-71.
8. 8. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283:381-90.
9. 9. Moore J, Vallette G, Darque A, Sommadossi J-P, Zhou X-J. Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine and stavudine in peripheral mononuclear blood cells of HIV-infected patients by HPLC/MS/MS. J Mass Spectrom (in press).
10. 10. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298) [abstract 2]. In: 5th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:79.
11. 11. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Disease. N Engl J Med 1990; 322:941-9.
12. 12. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-9.
13. 13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
14. 14. Flexner C. HTV-protease inhibitors. N Engl J Med 1998; 338:1281-92.